Try our beta test site
16 studies found for:    weill AND intravenous (iv) therapy | Open Studies
Show Display Options
Rank Status Study
1 Recruiting BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
Conditions: Metastatic Cancer;   Cancer;   Solid Tumor
Interventions: Drug: BP31510 monotherapy;   Drug: BP31510 in combination with chemotherapy
2 Recruiting Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Conditions: Glioblastoma Multiforme;   Fibrillary Astrocytoma of Brain;   Glioma of Brainstem;   Anaplastic Astrocytoma;   Pilomyxoid Astrocytoma;   Mixed Oligodendroglioma-Astrocytoma;   Brain Stem Glioma;   Diffuse Intrinsic Pontine Glioma
Intervention: Drug: SIACI of Erbitux and Bevacizumab
3 Recruiting J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts
Condition: Prostate Cancer
Intervention: Drug: huJ591
4 Recruiting Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Drug: ABVD;   Drug: BEACOPP;   Radiation: radiation therapy
5 Recruiting A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: REGN1979 multiple dose levels
6 Not yet recruiting Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas
Conditions: Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma
Interventions: Drug: Venetoclax;   Drug: Rituximab;   Drug: Etoposide;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Doxorubicin Hydrochloride
7 Recruiting Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Conditions: Metastatic Prostate Cancer;   Pain
Intervention: Drug: Radium-223
8 Recruiting Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
Condition: Metastatic Pancreas Adenocarcinoma
Interventions: Drug: 5FU;   Drug: nab-paclitaxel;   Drug: bevacizumab;   Drug: calcium leucovorin;   Drug: oxaliplatin
9 Recruiting The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
Condition: Delirium
Interventions: Drug: Ketamine (0.5 mg/kg);   Drug: Normal Saline (placebo);   Drug: Ketamine (1 mg/kg)
10 Recruiting A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Durvalumab;   Drug: Pomalidomide;   Drug: Dexamethasone
11 Recruiting A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Durvalumab;   Drug: Lenalidomide;   Drug: Dexamethasone
12 Recruiting Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Conditions: HER-2 Positive Breast Cancer;   Metastatic Neoplasm
Interventions: Biological: Margetuximab;   Biological: Trastuzumab;   Drug: Capecitabine;   Drug: Eribulin;   Drug: Gemcitabine;   Drug: Vinorelbine
13 Recruiting 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037);   Drug: Placebo
14 Recruiting Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Elotuzumab;   Drug: Pomalidomide;   Drug: Dexamethasone
15 Recruiting A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, and Erivedge Treatment Targeted Against Certain Mutations in Cancer Patients
Condition: Neoplasms
Interventions: Drug: Cobimetinib [Cotellic];   Drug: Erlotinib [Tarceva];   Drug: Pertuzumab [Perjeta];   Drug: Trastuzumab [Herceptin];   Drug: Vemurafenib [Zelboraf];   Drug: Vismodegib [Erivedge]
16 Recruiting A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: CC-122;   Drug: Ibrutinib;   Drug: Obinutuzumab

Study has passed its completion date and status has not been verified in more than two years.